C-WKDFIntraClear Biologics
gene/enzyme therapy, damage repair, ageing biomarkers
clearinggene therapy
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
All companiesC-WKDF
C-WKDFC-WKDFgene/enzyme therapy, damage repair, ageing biomarkers
0-100 chain-logic scale · 15 dimensions · scored on public evidence
IntraClear Biologics gene/enzyme therapy, damage repair, ageing biomarkers
IntraClear Biologics describes itself as a new generation bioengineering company focused on putting ageing under medical control. Its work targets molecular and cellular damage that accumulates with age, especially lipofuscin and 7-ketocholesterol. The company also offers bioinformatics services for sequencing analysis, mitochondrial diagnostics, mtDNA fragility prediction, haplogroup reconstruction, and mutational spectra reconstruction.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
IntraClear Biologics — Far from goals · Bottom quartile. Derived deterministically from 4 extracted project(s). Most-advanced status: undisclosed. Band: far. Modifiers: +5 depth (4 programs at undisclosed).…
Source: Deterministic